review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.YEXMP.2007.12.002 |
P698 | PubMed publication ID | 18279851 |
P50 | author | Zdenek Kolar | Q39185544 |
Marián Hajdúch | Q73099106 | ||
Radek Trojanec | Q73220350 | ||
P2093 | author name string | I Uberall | |
J Berkovcová | |||
P2860 | cites work | The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease | Q24677033 |
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
Cell signaling by receptor tyrosine kinases | Q27860474 | ||
Untangling the ErbB signalling network | Q27860884 | ||
Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 | ||
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
Cancer statistics, 2005 | Q29617572 | ||
The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
Chronic hepatitis B virus infection in Asian countries | Q30980179 | ||
Receptor signaling: when dimerization is not enough | Q33723925 | ||
c-erbB3 protein expression in ovarian cancer | Q33841195 | ||
EGF mutant receptor vIII as a molecular target in cancer therapy | Q33950534 | ||
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. | Q33968565 | ||
Gastric adenocarcinoma: pathomorphology and molecular pathology | Q34226916 | ||
The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
EGFR and cancer prognosis | Q34399312 | ||
ErbB and HB-EGF signaling in heart development and function. | Q34498400 | ||
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material | Q34535370 | ||
c-erbB-2 in breast cancer: development of a clinically useful marker | Q34683975 | ||
Prognostic and predictive value of HER2/neu oncogene in breast cancer | Q34954864 | ||
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis | Q34986549 | ||
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
Signal transduction and oncogenesis by ErbB/HER receptors | Q35669114 | ||
The HER receptor family: a rich target for therapeutic development | Q35669122 | ||
Focus on gastric cancer. | Q35681321 | ||
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer | Q35788601 | ||
Biological significance of c-erbB family oncogenes in head and neck cancer | Q36078091 | ||
Expression of c-erbB3 protein in primary breast carcinomas | Q36115645 | ||
Cancer biomarkers: knowing the present and predicting the future | Q36429381 | ||
Epidermal growth factor receptor biology in head and neck cancer | Q36500973 | ||
ErbB receptor negative regulatory mechanisms: implications in cancer | Q36545883 | ||
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma | Q36622264 | ||
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group) | Q36695522 | ||
ErbB2 is required for ductal morphogenesis of the mammary gland | Q37704948 | ||
Status of HER-2 in male and female breast carcinoma | Q38458762 | ||
Estimates of the worldwide mortality from 25 cancers in 1990. | Q39358305 | ||
Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas | Q40554806 | ||
Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases | Q40639249 | ||
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells | Q40676718 | ||
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma | Q41053705 | ||
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
The autocrine loop of TGF-alpha/EGFR and brain tumors | Q41687874 | ||
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII) | Q42004592 | ||
Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma | Q42491365 | ||
Role of exon-16-deleted HER2 in breast carcinomas | Q42803579 | ||
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. | Q43779560 | ||
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability | Q45149773 | ||
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast | Q46402523 | ||
Enhanced TGFalpha-EGFR expression and P53 gene alterations contributes to gastric tumors aggressiveness. | Q47218285 | ||
Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. | Q47304057 | ||
Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. | Q53345476 | ||
ERBB2 kinase domain mutation in a gastric cancer metastasis. | Q53609172 | ||
Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. | Q53633593 | ||
Her-2-neu expression and progression toward androgen independence in human prostate cancer. | Q53800928 | ||
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. | Q53878417 | ||
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. | Q54242652 | ||
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. | Q55477802 | ||
Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms | Q71048246 | ||
Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases | Q72807107 | ||
Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer | Q73339030 | ||
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer | Q73358692 | ||
Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer | Q73937759 | ||
ErbB kinases and NDF signaling in human prostate cancer cells | Q73945597 | ||
Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival | Q74176628 | ||
Activation of epidermal growth factor receptor kinase in gastric carcinoma: a preliminary study | Q74194748 | ||
HER2 protein expression and gene amplification in androgen-independent prostate cancer | Q74317132 | ||
Mutations and amplification of oncogenes in endometrial cancer | Q77785073 | ||
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
Endometrial cancer | Q81833884 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 79-89 | |
P577 | publication date | 2008-01-05 | |
P1433 | published in | Experimental and Molecular Pathology | Q15767470 |
P1476 | title | The status and role of ErbB receptors in human cancer | |
P478 | volume | 84 |
Q39552974 | A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. |
Q54945917 | A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. |
Q38120594 | C-erbB2/HER2 in human gliomas, medulloblastomas, and meningiomas: a minireview |
Q53533429 | Cancer Nanotechnology: Opportunities for Prevention, Diagnosis, and Therapy. |
Q37363872 | Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma |
Q33959887 | Clinical relevance of KRAS in human cancers |
Q51062789 | Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma. |
Q34103963 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention |
Q33932286 | Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity |
Q36924803 | Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo |
Q37634419 | Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma |
Q55070997 | EGFR signaling patterns are regulated by its different ligands. |
Q38552978 | EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection |
Q44449930 | ERBB3 as an independent prognostic marker for nasopharyngeal carcinoma |
Q33976619 | Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer |
Q37263452 | ErbB receptors in the biology and pathology of the aerodigestive tract |
Q35755192 | ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer |
Q41816395 | Fasciclin 2, the Drosophila orthologue of neural cell-adhesion molecule, inhibits EGF receptor signalling |
Q43912153 | Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma |
Q44663445 | Fine needle aspirate cell blocks are reliable for detection of hormone receptors and HER-2 by immunohistochemistry in breast carcinoma |
Q37355586 | HER2-positive male breast cancer: an update. |
Q42288961 | HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice. |
Q36986849 | Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy |
Q37391086 | Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin |
Q36925229 | Inherited and acquired alterations in development of breast cancer. |
Q35083740 | KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations |
Q92618791 | Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma |
Q31036763 | Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line |
Q38758386 | Regulatory mechanisms of EGFR signalling during Drosophila eye development |
Q37691771 | Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p |
Q37600910 | Targeting the EGF receptor ectodomain in the context of cancer |
Q37856405 | The effect of cell-ECM adhesion on signalling via the ErbB family of growth factor receptors |
Q39028181 | The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer |
Q37015715 | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers |
Q38905388 | Transcriptome meta-analysis reveals dysregulated pathways in nasopharyngeal carcinoma |
Q34569071 | Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. |
Search more.